{"organizations": [], "uuid": "ef7e4df88bc4a59116b57a83eef1b4a91435630a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-retrophin-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Retrophin reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T01:15:00.000+02:00", "replies_count": 0, "uuid": "ef7e4df88bc4a59116b57a83eef1b4a91435630a"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-retrophin-reports-4q-loss.html", "ord_in_thread": 0, "title": "Retrophin reports 4Q loss", "locations": [], "entities": {"persons": [{"name": "retrophin", "sentiment": "negative"}], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "retrophin inc.", "sentiment": "negative"}, {"name": "rtrx", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO (AP) _ Retrophin Inc. (RTRX) on Tuesday reported a loss of $17.6 million in its fourth quarter.\nOn a per-share basis, the San Diego-based company said it had a loss of 55 cents. Earnings, adjusted for non-recurring costs and pretax expenses, came to 7 cents per share.\nThe drug developer posted revenue of $42.2 million in the period.\nFor the year, the company reported that its loss widened to $59.7 million, or $1.54 per share. Revenue was reported as $154.9 million.\nRetrophin shares have risen 13 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $23.88, a rise of 13 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on RTRX at https://www.zacks.com/ap/RTRX", "external_links": [], "published": "2018-02-28T01:15:00.000+02:00", "crawled": "2018-02-28T01:27:24.011+02:00", "highlightTitle": ""}